Syngeneic graft-versus-host disease: A report of two cases and literature review

Bone Marrow Transplantation

Volumn 32, Issue 5, 2003, Pages 535-539

  Latif, T ^a   Pohlman, B ^a   Kalaycio, M ^a   Sobecks, R ^a   Hsi, E D ^b   Andresen, S ^a   Bolwell, B J ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Graft versus host disease (GVHD); Immunosuppresion; Syngeneic graft versus host disease (SGVHD)

Indexed keywords

BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; PREDNISONE; STEROID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CASE REPORT; COLITIS; DISEASE SEVERITY; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISOGRAFT; MALE; MEDICAL LITERATURE; MORBIDITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ADULT; AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; GRAFT VS HOST REACTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RECURRENCE; TRANSPLANTATION, ISOGENEIC;

EID: 0141590280     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704171     Document Type: Article

References (26)

1. Billingham RE, Brent L. A simple method for inducing skin allograft in mice. Transplant Bull 1957; 4: 67.
2. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of graft-versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-versus-host Disease: Immunology, Pathophysiology and Treatment. Marcel Dekker: New York, 1990, pp 311-336.
3. Hess AD, Horowitz L, Beschorner WE et al. Development of graft-versus-host disease like syndrome in cyclosporin-treated rats after syngeneic bone marrow transplant. J Exp Med 1985; 161: 718-730.
4. Einsele H, Ehninger G, Schneider EM et al. High frequency of graft versus host like syndromes following syngeneic bone marrow transplantation. Transplantation 1988; 45: 579-585.
5. Rappeport JM, Mihm M, Reinherz E et al. Acute graft-versus-host disease in recipients of bone marrow transplant from identical donors. Lancet 1979; ii: 717-720.
6. Gluckman E, Devergie A, Sohier J et al. Graft-versus-host disease in recipients of syngeneic bone marrow. Lancet 1980; i: 253-254.
7. Hood AF, Vogelsang GB, Black LP et al. Acute graft-versus-host disease, development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745-750.
8. Deane M, Singer C, Lawler M et al. Acute skin GVHD following syngeneic BMT for CLL. Bone Marrow Transplant 1998; 22: 1207-1209.
9. Hwang WY, Goh YT, Tan CH et al. Severe acute graft-versus-host disease occurring after syngeneic BMT for AML in a patient not given prior cyclosporin A therapy. Bone Marrow Transplant 2000; 25: 205-207.
10. Wolin MJ, Rigor RL. Acute graft-versus-host disease in a recipient of a twin blood cell transplant. Bone Marrow Transplant 1996; 17: 125-126.
11. Spaner D, Lowsky R, Fyles G et al. Acute intestinal graft-versus-host disease in a syngeneic bone marrow transplant recipient. Transplantation 1998; 66: 1251-1253.
12. Billingham RE. The biology of graft-versus-host reaction. Harvey Lect 1966-67; 62: 21-78.
13. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
14. Sale GE, Lerner KG, Barker EA et al. The skin biopsy in the diagnosis of graft-versus-host disease in man. Am J Pathol 1977; 89: 621-636.
15. Glazier A, Tutschka PJ, Farmer ER et al. Graft-versus-host disease in cyclosporin A treated rats after syngeneic and autologous bone marrow transplant. J Exp Med 1983; 158: 1-8.
16. Gao EK, Lo D, Cheney RT et al. Abnormal differentiation of thymocytes in mice treated with cyclosporine A. Nature 1988; 336: 176.
17. Shi Y, Sahai BM, Green DR. Cyclosporine A inhibits activation-induced cell death in T cell hybridomas and thymocytes. Nature 1989; 339: 625.
18. Cheney RT, Sprent J. Capacity of cyclosporine to induce autograft-versus-host disease and impair intrathymic T cell differentiation. Transplant Proc 1985; 17: 528.
19. Ferrara J, Burakoff S. The pathophysiology of graft-versus-host disease in a murine bone marrow transplant model. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds). Graft-versus-host Disease: Immunology, Pathophysiology and Treatment. Marcel Dekker: New York, 1990, pp 9-29.
20. Sale GE, Shulman HM, Hackman RC. Pathophysiology of bone marrow transplantation. In: Forman SJ, Blume KG, Thomas Ed (eds). Pathology of Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, 1994, p 189.
21. Biddeson WE, Shaw S, Nelson DL. Virus specificity of human influenza virus immune cytotoxic T cells. J Immunol 1979; 122: 660-664.
22. Drobyski W, Thibodeau S, Truitt RL et al. Third party mediated graft rejection and graft-versus-host disease after T cell depleted bone marrow transplant as demonstrated by hypervariable DNA probes and HLA DR polymorphism. Blood 1989; 74: 2285-2294.
23. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 315-321.
24. Jones R, Vogelsang GB, Hess A et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754-757.
25. Morris LE, Vogelsang GB, Bright E et al. Immune reconstitution in cyclosporine A induced autologous graft-versus-host disease. Blood 1992; 80 (Suppl 1): 534 (Abstr.).
26. Kennedy MJ. Induced autologous graft-versus-host disease for treatment of cancer. Cancer Treatment Rev 1994; 20: 97-103.